Skip to main content

Advertisement

SpringerLink
Log in

Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma

  • Clinical Study - Patient Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Several biomarkers have been identified as prognostic factors in primary central nervous system lymphoma (PCNSL). However, the correlation between the histogenetic origin of PCNSL and the response to therapy is still unclear. To elucidate the utility of immunophenotypic markers in predicting clinical outcomes, we investigated 27 immunocompetent patients with PCNSL treated with high-dose methotrexate therapy. Of the 27 patients, 25 received whole-brain radiotherapy after high-dose methotrexate. Immunostaining for CD5, CD10, BCL-6, and MUM-1 was used to determine the immunophenotypic profile of diffuse large B-cell lymphoma of PCNSL. We then evaluated whether immunophenotypic markers were associated with the response to therapy or patients’ survival. The response to induction high-dose methotrexate therapy was determined by magnetic resonance imaging after three courses of i.v. high-dose methotrexate. We categorized B-cell lymphomas into three known subtypes: germinal center B-cell (GCB), activated-GCB, and post-GCB subtypes according to immunohistochemical profile. All the BCL-6-positive samples were co-positive for MUM-1 and therefore classified into activated-GCB subtype. BCL-6 expression in this study was associated with poor progression-free survival (P = 0.038). No immunophenotypic markers or subtypes had a significant effect on the response to high-dose methotrexate therapy. However, the response itself was a significant predictor for both progression-free survival (P < 0.001) and overall survival (P = 0.003). Further investigation is needed to assess BCL-6 as a potential prognostic factor in PCNSL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Coté TR, Manns A, Hardy CR et al (1996) Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J Natl Cancer Inst 88:675–679

    Article  PubMed  Google Scholar 

  2. Olson JE, Janney CA, Rao RD et al (2002) The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 95:1504–1510

    Article  PubMed  Google Scholar 

  3. Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18:3144–3150

    CAS  PubMed  Google Scholar 

  4. DeAngelis LM, Seiferheld W, Schold SC et al (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20:4643–4648

    Article  PubMed  Google Scholar 

  5. Paulus W (1999) Classification, pathogenesis and molecular pathology of primary CNS lymphomas. J Neurooncol 43:203–208

    Article  CAS  PubMed  Google Scholar 

  6. Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511

    Article  CAS  PubMed  Google Scholar 

  7. Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937–1947

    Article  PubMed  Google Scholar 

  8. Dent AL, Shaffer AL, Yu X et al (1997) Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 276:589–592. doi:10.1126/science.276.5312.589

    Article  CAS  PubMed  Google Scholar 

  9. Dogan A, Bagdi E, Munson P et al (2000) CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 24:846–852

    Article  CAS  PubMed  Google Scholar 

  10. Falini B, Fizzotti M, Pucciarini A et al (2000) A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 95:2084–2092

    CAS  PubMed  Google Scholar 

  11. Natkunam Y, Warnke RA, Montgomery K (2001) Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 14:686–694

    Article  CAS  PubMed  Google Scholar 

  12. Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282. doi:10.1182/blood-2003-05-1545

    Article  CAS  PubMed  Google Scholar 

  13. Chang CC, McClintock S, Cleveland RP et al (2004) Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 28:464–470

    Article  PubMed  Google Scholar 

  14. Camilleri-Broët S, Crinière E, Broët P et al (2006) A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107:190–196

    Article  PubMed  Google Scholar 

  15. Lin CH, Kuo KT, Chuang SS et al (2006) Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res 12:1152–1156

    Article  CAS  PubMed  Google Scholar 

  16. Levy O, Deangelis LM, Filippa DA et al (2008) Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer 112:151–156

    Article  PubMed  Google Scholar 

  17. Matolcsy A, Chadburn A, Knowles DM (1995) De novo CD5-positive and Richter’s syndrome–associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol 147:207–216

    CAS  PubMed  Google Scholar 

  18. Yamaguchi M, Seto M, Okamoto M et al (2002) De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 99:815–821

    Article  CAS  PubMed  Google Scholar 

  19. Maeshima AM, Taniguchi H, Nomoto J et al (2009) Secondary CD5+ diffuse large B-cell lymphoma not associated with transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter syndrome). Am J Clin Pathol 131:339–346

    Article  CAS  PubMed  Google Scholar 

  20. Braaten KM, Betensky RA, de Leval L et al (2003) BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 9:1063–1069

    CAS  PubMed  Google Scholar 

  21. Sugita Y, Tokunaga O, Nakashima A et al (2004) SHP-1 expression in primary central nervous system B-cell lymphomas in immunocompetent patients reflects maturation stage of normal B cell counterparts. Pathol Int 54:659–666

    Article  CAS  PubMed  Google Scholar 

  22. McAllister LD, Doolittle ND, Guastadisegni PE et al (2000) Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46:51–60

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Hiroyuki Momota

    Present address: Department of Neurosurgery, Nagoya University, Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan

Authors and Affiliations

  1. Neurosurgery Division, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Hiroyuki Momota, Yoshitaka Narita, Yasuji Miyakita, Aya Shinomiya & Soichiro Shibui

  2. Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan

    Akiko M. Maeshima

  3. Department of Neurosurgery, Tokyo Women’s Medical University, Tokyo, Japan

    Takashi Maruyama & Yoshihiro Muragaki

Authors
  1. Hiroyuki Momota
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshitaka Narita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akiko M. Maeshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasuji Miyakita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aya Shinomiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takashi Maruyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshihiro Muragaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Soichiro Shibui
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroyuki Momota.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Momota, H., Narita, Y., Maeshima, A.M. et al. Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma. J Neurooncol 98, 341–348 (2010). https://doi.org/10.1007/s11060-009-0078-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-009-0078-z

Keywords

Search

Navigation